- United Therapeutics press release ( NASDAQ: UTHR ): Q2 GAAP EPS of $2.41 misses by $1.55 .
- Revenue of $466.9M (+4.6% Y/Y) beats by $5.84M .
- “The recent approval and launch of Tyvaso DPI, coupled with the Medicare coverage decision for Tyvaso in PH-ILD, will provide additional momentum toward reaching our goal of 6,000 patients on Tyvaso by the end of the year.” said Michael Benkowitz, President and Chief Operating Officer of United Therapeutics.
For further details see:
United Therapeutics GAAP EPS of $2.41 misses by $1.55, revenue of $466.9M beats by $5.84M